Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

100%

7 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4

6(85.7%)

Phase 3

1(14.3%)

7Total

Phase 4(6)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04089787Phase 4Completed

Shortened Antibiotic Treatment of 5 Days in Community-Acquired Pneumonia

Role: lead

NCT04904406Phase 4Completed

Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals

Role: lead

NCT04291768Phase 4Recruiting

Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia

Role: lead

NCT04345289Phase 3Terminated

Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia

Role: lead

NCT04903847Phase 4Unknown

Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil

Role: lead

NCT04875819Phase 4Recruiting

Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV

Role: lead

NCT03514446Phase 4Unknown

Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia

Role: lead

All 7 trials loaded